Elevated brain-derived cell-free DNA among patients with first psychotic episode - a proof-of-concept study
- The Hebrew University-Hadassah Medical School, Israel
- Jerusalem Mental Health Center, Israel
- Karolinska Institutet Innovations, Sweden
- Hebrew University of Jerusalem, Israel
Abstract
Schizophrenia is a common, severe and debilitating psychiatric disorder. Despite extensive research there is as yet no biological marker that can aid in its diagnosis and course prediction. This precludes early detection and intervention. Imaging studies suggest brain volume loss around the onset and over the first few years of schizophrenia, and apoptosis has been proposed as the underlying mechanism. Cell-free DNA fragments (cfDNA) are released into the bloodstream following cell death. Tissue-specific methylation patterns allow the identification of the tissue origins of cfDNA. We developed a cocktail of brain specific DNA methylation markers, and used it to assess the presence of brain-derived cfDNA in the plasma of patients with a first psychotic episode. We detected significantly elevated neuron- (p=0.0013), astrocyte- (p=0.0016), oligodendrocyte- (p=0.0129) and whole brain-derived (p=0.0012) cfDNA in the plasma of patients during their first psychotic episode (n=29), compared with healthy controls (n=31). Increased cfDNA levels were not correlated with psychotropic medications use. Area Under the Curve (AUC) was 0.77, with 65% sensitivity at 90% specificity in patients with a psychotic episode. Potential interpretations of these findings include increased brain cell death, disruption of the blood-brain barrier or a defect in clearance of material from dying brain cells. Brain-specific cfDNA methylation markers can potentially assist early detection and monitoring of schizophrenia and thus allow early intervention and adequate therapy.
Data availability
All relevant data including information on the markers used (coordinates and primer sequences), detailed information on patients and donors and the raw data on values of each methylation marker in each sample is provided in Source data 1. This data was used to generate the graphs shown in the paper.Detailed PCR conditions are detailed in the Materials and methods section and were published in a recent paper. Code is uploaded to GitHub as described in the paper (https://github.com/Joshmoss11/btseq).
Article and author information
Author details
Funding
Award of the National Institute of Psychobiology in Israel and the Israeli Society of Biological Psychiatry
- Asael Lubotzky
Israel Science Foundation
- Yuval Dor
Grail
- Yuval Dor
Award of the National Institute of Psychobiology in Israel and the Israeli Society of Biological Psychiatry
- Ilana Pelov
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: This study was conducted according to protocols approved by the Jerusalem Mental Health Center Institutional Review Board, in accordance with the Declaration of Helsinki (HMO-14-0198).We recruited men and women over 18 years of age, who have developed psychotic symptoms for the first time in their life within the last year and were admitted to the acute psychiatric units of the Jerusalem Mental Health Center in Israel.Blood samples were obtained after the initial stabilization and partial remission of the psychotic symptoms which enabled the patients to give written informed consent for participation in the study. The time achieving stability was different for each individual patient, but the majority stabilized within 4 weeks (79%). The patients were asked to complete a short questionnaire regarding demographic details, current physical condition, the onset of present symptoms and drug use. The recruitment was done following the approval of the study's protocol by the Jerusalem Mental Health Center Institutional Review Board. Patients with acute medical conditions in the week prior to the blood sampling were excluded from the study.31 adult volunteers participated in the study as unpaid healthy controls.
Copyright
© 2022, Lubotzky et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,734
- views
-
- 317
- downloads
-
- 13
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Elevated brain-derived cell-free DNA among patients with first psychotic episode - a proof-of-concept study
eLife 11:e76391.
https://doi.org/10.7554/eLife.76391
Further reading
-
- Developmental Biology
- Genetics and Genomics
Paternal obesity has been implicated in adult-onset metabolic disease in offspring. However, the molecular mechanisms driving these paternal effects and the developmental processes involved remain poorly understood. One underexplored possibility is the role of paternally induced effects on placenta development and function. To address this, we investigated paternal high-fat diet-induced obesity in relation to sperm histone H3 lysine 4 tri-methylation signatures, the placenta transcriptome, and cellular composition. C57BL6/J male mice were fed either a control or high-fat diet for 10 weeks beginning at 6 weeks of age. Males were timed-mated with control-fed C57BL6/J females to generate pregnancies, followed by collection of sperm, and placentas at embryonic day (E)14.5. Chromatin immunoprecipitation targeting histone H3 lysine 4 tri-methylation (H3K4me3) followed by sequencing (ChIP-seq) was performed on sperm to define obesity-associated changes in enrichment. Paternal obesity corresponded with altered sperm H3K4me3 at promoters of genes involved in metabolism and development. Notably, altered sperm H3K4me3 was also localized at placental enhancers. Bulk RNA-sequencing on placentas revealed paternal obesity-associated sex-specific changes in expression of genes involved in hypoxic processes such as angiogenesis, nutrient transport, and imprinted genes, with a subset of de-regulated genes showing changes in H3K4me3 in sperm at corresponding promoters. Paternal obesity was also linked to impaired placenta development; specifically, a deconvolution analysis revealed altered trophoblast cell lineage specification. These findings implicate paternal obesity effects on placenta development and function as one potential developmental route to offspring metabolic disease.
-
- Genetics and Genomics
The use of siblings to infer the factors influencing complex traits has been a cornerstone of quantitative genetics. Here, we utilise siblings for a novel application: the inference of genetic architecture, specifically that relating to individuals with extreme trait values (e.g. in the top 1%). Inferring the genetic architecture most relevant to this group of individuals is important because they are at the greatest risk of disease and may be more likely to harbour rare variants of large effect due to natural selection. We develop a theoretical framework that derives expected distributions of sibling trait values based on an index sibling’s trait value, estimated trait heritability, and null assumptions that include infinitesimal genetic effects and environmental factors that are either controlled for or have combined Gaussian effects. This framework is then used to develop statistical tests powered to distinguish between trait tails characterised by common polygenic architecture from those that include substantial enrichments of de novo or rare variant (Mendelian) architecture. We apply our tests to UK Biobank data here, although we note that they can be used to infer genetic architecture in any cohort or health registry that includes siblings and their trait values, since these tests do not use genetic data. We describe how our approach has the potential to help disentangle the genetic and environmental causes of extreme trait values, and to improve the design and power of future sequencing studies to detect rare variants.
